Success Metrics

Active Trials
9(90%)

Phase Distribution

Ph phase_3
6
60%
Ph phase_2
4
40%

Phase Distribution

0

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
6(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

10

all time

Status Distribution
Active(10)

Detailed Status

Recruiting7
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
9
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 24 (40.0%)
Phase 36 (60.0%)

Trials by Status

recruiting770%
active_not_recruiting220%
not_yet_recruiting110%

Recent Activity

9 active trials
Showing 5 of 10
recruitingphase_3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891
recruitingphase_2

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961
recruitingphase_2

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07137598
recruitingphase_3

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878
recruitingphase_3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06819891Phase 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Recruiting
NCT06863961Phase 2

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Recruiting
NCT07137598Phase 2

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

Recruiting
NCT06819878Phase 3

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Recruiting
NCT06588855Phase 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
NCT07158242Phase 3

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Recruiting
NCT07298421Phase 3

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

Not Yet Recruiting
NCT07223697Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Recruiting
NCT05910528Phase 2

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

Active Not Recruiting
NCT06589986Phase 3

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Active Not Recruiting

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10